The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Wed, July 6, 2022 | 19:22
GC Pharma set to produce Sputnik V vaccine
Posted : 2021-02-09 09:03
Updated : 2021-02-09 16:58
Print Preview
Font Size Up
Font Size Down
A medical worker shows a vial of Sputnik V vaccine during COVID-19 vaccinations at a clinic near Moscow in this December 2020 file photo. / Reuters-Yonhap
A medical worker shows a vial of Sputnik V vaccine during COVID-19 vaccinations at a clinic near Moscow in this December 2020 file photo. / Reuters-Yonhap

Government considers introducing Sputnik V to Korea

By Park Jae-hyuk

GC Pharma is emerging as a potential contract manufacturing organization (CMO) of Russia's COVID-19 vaccine Sputnik V, according to media reports and industry officials, Monday.

Korea Disease Control and Prevention Agency (KDCA) Commissioner Jeong Eun-kyeong also said that day that the government is considering introducing the Russian vaccine to cope with uncertainties over mutations and supply issues.

The Russian Direct Investment Fund (RDIF), the country's sovereign wealth fund that invested in the Gamaleya National Research Center of Epidemiology and Microbiology for the development of the vaccine, chose Hankook Korus Pharm, a subsidiary of biotech company GL Rapha, as a Korean manufacturing partner last November.

The small pharmaceutical firm has produced Sputnik V at its factory in Chuncheon, Gangwon Province, to export the entire output to the Middle East. Its annual production capacity for the vaccine, named after the world's first satellite that the Soviet Union launched in 1957, is about 150 million doses.

Industry sources said the RDIF is looking for another manufacturer here because more countries want to import the Russian vaccine, after the Lancet, one of the world's oldest and most respected medical journals, confirmed the vaccine's efficacy at 91.6 percent.

GC Pharma has been mentioned as the strongest candidate, given the drug maker signed an agreement last October with the Coalition for Epidemic Preparedness Innovations (CEPI) on reserving its vaccine production capacity to produce CEPI-funded vaccines.

At the time of the agreement, CEPI said GC Pharma will produce at least one of the vaccine candidates in CEPI's portfolio, adding the capacity is estimated to exceed 500 million vaccine doses.

If the RDIF signs an agreement with GC Pharma, the Korean firm is expected to produce Sputnik V at its factory in Ochang, North Chungcheong Province.

GC Pharma has reiterated that it cannot confirm the report until the conclusion of a contract, as the company had also said when it was mentioned as a Korean CMO of Moderna's COVID-19 vaccine last December.

However, the company reportedly told local securities analysts in a private meeting last month that it had received proposals from multiple COVID-19 vaccine developers and rearranged the production schedule at its Ochang factory.

"The shortage of vaccine production facilities seems inevitable due to the development of a variety of vaccines, so the contract manufacturing of GC Pharma's COVID-19 vaccine is considered a matter of the timing of the announcement," Hana Financial Investment analyst Sun Min-jung said.

The RDIF has yet to comment on whether it is in talks with GC Pharma or the Korean government, but its CEO Kirill Dmitriev said in a previous interview with The Korea Times that the sovereign wealth fund was in talks with two major Korean pharmaceutical companies.

"We aim to make it available for use in countries globally and to create strategic partnerships for vaccine production in all parts of the world, including South Korea," he said at that time.


Emailpjh@koreatimes.co.kr Article ListMore articles by this reporter
 
LG
  • Fashionista first lady draws polarized reactions
  • Price-conscious consumers flock to fresh food sales
  • Son Heung-min recalls experiencing racism in Germany, rejoicing at revenge in World Cup upset
  • Child porn website operator gets 2-yr prison term for concealing criminal proceeds
  • USFK member accused of alleged DUI on motorcycle
  • Korea's inflation soars to 24-year high, weighing on economy
  • June Huh becomes 1st scholar of Korean descent to win Fields Medal
  • Korea's inflation growth hits nearly 24-year high in June on fuel costs
  • US bill expresses concerns over proposed abolishment of Korean ministry of equality
  • Korea to expand nuclear power generation to 30% of total by 2030
  • Maroon 5's world tour image with Rising Sun design causes stir Maroon 5's world tour image with Rising Sun design causes stir
  • [INTERVIEW] How Frank Wildhorn became most popular musical composer in Korea [INTERVIEW] How Frank Wildhorn became most popular musical composer in Korea
  • [INTERVIEW] Yoon Doo-joon juggles music and acting for series 'Never Give Up' [INTERVIEW] Yoon Doo-joon juggles music and acting for series 'Never Give Up'
  • Enhypen returns with more intense music and performances Enhypen returns with more intense music and performances
  • Korea box office tops 15 mil. admissions in June Korea box office tops 15 mil. admissions in June
DARKROOM
  • Afghanistan earthquake killed more than 1,000

    Afghanistan earthquake killed more than 1,000

  • Divided America reacts to overturn of Roe vs. Wade

    Divided America reacts to overturn of Roe vs. Wade

  • Namaste: Yogis to celebrate International Yoga Day

    Namaste: Yogis to celebrate International Yoga Day

  • Poor hit harder by economic crisis

    Poor hit harder by economic crisis

  • Roland Garros 2022

    Roland Garros 2022

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group